Weighing the Benefits of the Gardasil Vaccine

Many parents are interested in vaccines expected to protect women 's second most common cancer each year. In particular, when 11,000 women are diagnosed as cervical cancer every year, 3,700 people die as a result. Gardasil is a series of three-shot immunizations for girls aged 9 to 26. These three shots prevent four different human papillomavirus strains that may cause cervical cancer.

HPV vaccine (Gardasil) has been used by girls in Ireland since 2010. It is recommended by the World Health Organization, and it seems to be a general consensus that it is a safe, effective and life - saving vaccine. More than 165 million doses are administered worldwide. It can protect up to 70% of cervical cancer. TheJournal.ie published a fact review on the effectiveness of many clinical trials of Gardasil. In Ireland, 948 side effects have been reported in the first 5 years of the vaccine. This is the dose of 590,694 Gardasil - so apparently a serious reaction is rare. Most adverse reactions are consistent with expectations (headache, local pain, rash etc.), short lived.

From the outset, two potential HPV vaccines (Merck's Gardsil and GlaxoSmithKline's Cervarix are sold outside the United States), their potential benefits are oversold and there are many risks, especially with inappropriate use. Placebo independent researchers can only criticize regulatory white evidence. A few recent letters announced at the British Medical Journal (BMJ) present several surprising figures explaining the amazing record of the vaccine.

There are currently four HPV vaccines on the market, namely, tetravalent and bivalent vaccines 7. In 2006, the FDA approved the 4-valent vaccine Gardasil (Merck) for girls and women ages 9 to 26 . Gardasil is indicated for the prevention of female precancerous lesions, genital warts and cervical cancer, vulval cancer and vaginal cancer caused by HPV types 6, 11, 16 and 18.1, 7, 8. On the same day, the FDA approved the bivalent HPV vaccine Cervarix manufactured by GlaxoSmithKline (GSK) to prevent reproductive warts caused by HPV of 6 and 11 in boys and boys aged 9 to 26 years . Bivalent vaccines are indicated for the prevention of cervical precancerous lesions in women 10 to 25 years of age and cancer associated with HPV types 16 and 18. 9 At the time of writing, Cervarix has not been approved by the FDA for use in men.